Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2023 Annual Meeting...
